| | |
Per Share and
Accompanying Warrant |
| |
Total
|
| ||||||
Combined Public offering price(1)
|
| | | $ | 16.00 | | | | | $ | 40,000,000 | | |
Underwriting discount(2)
|
| | | $ | 0.96 | | | | | $ | 2,400,000 | | |
Proceeds, before expenses, to us(3)
|
| | | $ | 15.04 | | | | | $ | 37,600,000 | | |
| | | | | S-1 | | | |
| | | | | S-2 | | | |
| | | | | S-5 | | | |
| | | | | S-7 | | | |
| | | | | S-10 | | | |
| | | | | S-13 | | | |
| | | | | S-14 | | | |
| | | | | S-15 | | | |
| | | | | S-17 | | | |
| | | | | S-25 | | | |
| | | | | S-27 | | | |
| | | | | S-35 | | | |
| | | | | S-36 | | | |
| | | | | S-37 | | | |
| | | | | S-38 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 11 | | | |
| | | | | 19 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 26 | | | |
| | | | | 28 | | | |
| | | | | 28 | | |
|
Public offering price per share
|
| | | | | | | | | $ | 16.00 | | |
|
Net tangible book value per share as of September 30, 2023
|
| | | $ | 7.29 | | | | | | | | |
|
Pro forma increase in net tangible book value per share attributable to the issuance of 97,360 shares of our common stock to TG Therapeutics
|
| | | | 0.40 | | | | | | | | |
|
Pro forma net tangible book value per share as of September 30, 2023
|
| | | | 7.69 | | | | | | | | |
|
Increase in pro forma net tangible book value per share after giving effect to the offering
|
| | | | 2.76 | | | | | | | | |
|
Pro forma as adjusted net tangible book value per share as of September 30, 2023
|
| | | | | | | | | | 10.45 | | |
|
Dilution per share to new investors participating in the offering
|
| | | | | | | | | $ | 5.55 | | |
| | |
Per
Share and Warrant |
| |
Total
Without Option to Purchase Additional Shares and Warrants |
| |
Total
With Option to Purchase Additional Shares and Warrants |
| |||||||||
Combined Public offering price
|
| | | $ | 16.00 | | | | | $ | 40,000,000 | | | | | $ | 46,000,000 | | |
Underwriting discounts and commissions paid by us
|
| | | $ | 0.96 | | | | | $ | 2,400,000 | | | | | $ | 2,760,000 | | |
Proceeds to us, before expenses
|
| | | $ | 15.04 | | | | | $ | 37,600,000 | | | | | $ | 43,240,000 | | |
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 2 | | | |
| | | | 4 | | | |
| | | | 5 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 11 | | | |
| | | | 19 | | | |
| | | | 21 | | | |
| | | | 22 | | | |
| | | | 26 | | | |
| | | | 28 | | | |
| | | | 28 | | |